Chemical: Prodrug

codeine

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for codeine

	Gene ?	Variant? (147)	Alternate Names ?	Chemicals ?	Alleles ? (+ chr strand)	Function ?	Amino Acid? Translation
VIP CA VA	CYP2D6	*1		acetaminophen amitriptyline atomoxetine bufuralol carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol hydrocodone imipramine levomepromazine maprotiline metoprolol mexiletine mianserin morphine nortriptyline oxycodone paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
CA VA	CYP2D6	*1xN		codeine	N/A	N/A	N/A
VIP CA VA	CYP2D6	*2		acetaminophen amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
VA	CYP2D6	*2A		codeine	N/A	N/A	N/A
CA VA	CYP2D6	*2xN		codeine hydrocodone oxycodone	N/A	N/A	N/A
VIP CA VA	CYP2D6	*3		amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
VIP CA VA	CYP2D6	*4		amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
CA VA	CYP2D6	*5		codeine debrisoquine dextromethorphan metoprolol	N/A	N/A	N/A
VIP CA VA	CYP2D6	*6		amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
VIP	CYP2D6	*9		amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
VIP CA VA	CYP2D6	*10		amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
VIP CA VA	CYP2D6	*17		amitriptyline atomoxetine bufuralol carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
VA	CYP2D6	*24		codeine	N/A	N/A	N/A
VA	CYP2D6	*26		codeine	N/A	N/A	N/A
VA	CYP2D6	*27		codeine	N/A	N/A	N/A
VIP VA	CYP2D6	*29		amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
VA	CYP2D6	*36		codeine	N/A	N/A	N/A
CA VA	CYP2D6	*40		codeine	N/A	N/A	N/A
VIP CA VA	CYP2D6	*41		amitriptyline atomoxetine carvedilol chlorpheniramine chlorpromazine citalopram clomipramine clozapine codeine debrisoquine desipramine dextromethorphan doxepin flecainide fluoxetine fluvoxamine gefitinib haloperidol imipramine maprotiline metoprolol mexiletine mianserin morphine nortriptyline paroxetine perhexiline perphenazine propafenone risperidone sparteine tamoxifen thioridazine timolol tolterodine tramadol yohimbine zuclopenthixol	N/A	N/A	N/A
CA VA	ABCB1	rs1045642	NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664	codeine	A > G	SNP	I1145I
VIP	CYP2D6	rs1065852	NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176		G > A	SNP	P34S
CA VA	ABCB1	rs1128503	NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317	codeine	A > G	SNP	G412G
VIP	CYP2D6	rs16947	NC_000022.10:g.42523943A=, NC_000022.10:g.42523943A>G, NC_000022.11:g.42127941G=, NC_000022.11:g.42127941G>A, NG_008376.3:g.7051C=, NG_008376.3:g.7051C>T, NM_000106.5:c.886C=, NM_000106.5:c.886C>T, NM_001025161.2:c.733C=, NM_001025161.2:c.733C>T, NP_000097.3:p.Arg296=, NP_000097.3:p.Arg296Cys, NP_001020332.2:p.Arg245=, NP_001020332.2:p.Arg245Cys, NT_187682.1:g.50282A=, NT_187682.1:g.50282A>G, NW_004504305.1:g.50268G=, NW_004504305.1:g.50268G>A, NW_009646208.1:g.13507G=, NW_009646208.1:g.13507G>A, XM_005278353.1:c.742C=, XM_005278353.1:c.742C>T, XM_005278354.1:c.586C=, XM_005278354.1:c.586C>T, XM_005278354.3:c.586C=, XM_005278354.3:c.586C>T, XM_011529966.1:c.886C=, XM_011529966.1:c.886C>T, XM_011529967.1:c.886C=, XM_011529967.1:c.886C>T, XM_011529968.1:c.886C=, XM_011529968.1:c.886C>T, XM_011529969.1:c.742C=, XM_011529969.1:c.742C>T, XM_011529970.1:c.733C=, XM_011529970.1:c.733C>T, XM_011529971.1:c.742C=, XM_011529971.1:c.742C>T, XM_011529972.1:c.843+233C>T, XM_011529972.1:c.843+233T>C, XM_011547541.1:c.586C=, XM_011547541.1:c.586C>T, XM_011547750.1:c.742T=, XM_011547750.1:c.742T>C, XM_011547751.1:c.670T=, XM_011547751.1:c.670T>C, XM_011547756.1:c.-2094A>G, XM_011547756.1:c.-2094G>A, XM_011548819.1:c.586C=, XM_011548819.1:c.586C>T, XP_005278410.1:p.Arg248=, XP_005278410.1:p.Arg248Cys, XP_005278411.1:p.Arg196=, XP_005278411.1:p.Arg196Cys, XP_011528268.1:p.Arg296=, XP_011528268.1:p.Arg296Cys, XP_011528269.1:p.Arg296=, XP_011528269.1:p.Arg296Cys, XP_011528270.1:p.Arg296=, XP_011528270.1:p.Arg296Cys, XP_011528271.1:p.Arg248=, XP_011528271.1:p.Arg248Cys, XP_011528272.1:p.Arg245=, XP_011528272.1:p.Arg245Cys, XP_011528273.1:p.Arg248=, XP_011528273.1:p.Arg248Cys, XP_011545843.1:p.Arg196=, XP_011545843.1:p.Arg196Cys, XP_011546052.1:p.Cys248=, XP_011546052.1:p.Cys248Arg, XP_011546053.1:p.Cys224=, XP_011546053.1:p.Cys224Arg, XP_011547121.1:p.Arg196=, XP_011547121.1:p.Arg196Cys, XR_430455.2:n.-1930A>G, XR_430455.2:n.-1930G>A, XR_952745.1:n.2000+233C>T, XR_952745.1:n.2000+233T>C, rs117039205, rs57836231		A > G	SNP	R296C
VA	OPRM1	rs1799971	NC_000006.11:g.154360797A>G, NC_000006.12:g.154039662A>G, NG_021208.1:g.34162A>G, NM_000914.4:c.118A>G, NM_001008503.2:c.118A>G, NM_001008504.3:c.118A>G, NM_001008505.2:c.118A>G, NM_001145279.3:c.397A>G, NM_001145280.3:c.-11+28644A>G, NM_001145281.2:c.47+29103A>G, NM_001145282.2:c.118A>G, NM_001145283.2:c.118A>G, NM_001145284.3:c.118A>G, NM_001145285.2:c.118A>G, NM_001145286.2:c.118A>G, NM_001285522.1:c.118A>G, NM_001285523.1:c.118A>G, NM_001285524.1:c.397A>G, NP_000905.3:p.Asn40Asp, NP_001008503.2:p.Asn40Asp, NP_001008504.2:p.Asn40Asp, NP_001008505.2:p.Asn40Asp, NP_001138751.1:p.Asn133Asp, NP_001138754.1:p.Asn40Asp, NP_001138755.1:p.Asn40Asp, NP_001138756.1:p.Asn40Asp, NP_001138757.1:p.Asn40Asp, NP_001138758.1:p.Asn40Asp, NP_001272451.1:p.Asn40Asp, NP_001272452.1:p.Asn40Asp, NP_001272453.1:p.Asn133Asp, NR_104348.1:n.252A>G, NR_104349.1:n.252A>G, NR_104350.1:n.252A>G, NR_104351.1:n.252A>G, XM_005267002.1:c.304A>G, XM_006715497.2:c.304A>G, XM_011535849.1:c.397A>G, XP_005267059.1:p.Asn102Asp, XP_006715560.1:p.Asn102Asp, XP_011534151.1:p.Asn133Asp, XR_245534.1:n.304A>G, XR_245535.1:n.304A>G, XR_245536.1:n.304A>G, XR_245537.1:n.304A>G, rs17181017, rs52818856, rs61596185	codeine	A > G	SNP	N40D
VA	ABCB1	rs2032582	NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018	codeine	A > C A > T	SNP	S893A
VIP	CYP2D6	rs28371706	NC_000022.10:g.42525772G>A, NC_000022.11:g.42129770G>A, NG_008376.3:g.5222C>T, NM_000106.5:c.320C>T, NM_001025161.2:c.320C>T, NP_000097.3:p.Thr107Ile, NP_001020332.2:p.Thr107Ile, NT_187682.1:g.52111G>A, NW_004504305.1:g.52097G>A, NW_009646208.1:g.15336G>A, XM_005278353.1:c.320C>T, XM_005278354.1:c.-532C>T, XM_005278354.3:c.-532C>T, XM_011529966.1:c.320C>T, XM_011529967.1:c.320C>T, XM_011529968.1:c.320C>T, XM_011529969.1:c.177C>T, XM_011529970.1:c.320C>T, XM_011529971.1:c.177C>T, XM_011529972.1:c.320C>T, XM_011547541.1:c.-532C>T, XM_011547750.1:c.177C>T, XM_011547751.1:c.-192C>T, XM_011547756.1:c.-265G>A, XM_011548819.1:c.-532C>T, XP_005278410.1:p.Thr107Ile, XP_011528268.1:p.Thr107Ile, XP_011528269.1:p.Thr107Ile, XP_011528270.1:p.Thr107Ile, XP_011528271.1:p.His59=, XP_011528272.1:p.Thr107Ile, XP_011528273.1:p.His59=, XP_011528274.1:p.Thr107Ile, XP_011546052.1:p.His59=, XR_430455.2:n.-101G>A, XR_952745.1:n.1477C>T, rs587777915, rs59604033		G > A	SNP	T107I
VIP	CYP2D6	rs28371725	NC_000022.10:g.42523805C>T, NC_000022.11:g.42127803C>T, NG_008376.3:g.7189G>A, NM_000106.5:c.985+39G>A, NM_001025161.2:c.832+39G>A, NT_187682.1:g.50144C>T, NW_004504305.1:g.50130C>T, NW_009646208.1:g.13369C>T, XM_005278353.1:c.841+39G>A, XM_005278354.1:c.685+39G>A, XM_005278354.3:c.685+39G>A, XM_011529966.1:c.985+39G>A, XM_011529967.1:c.985+39G>A, XM_011529968.1:c.985+39G>A, XM_011529969.1:c.841+39G>A, XM_011529970.1:c.832+39G>A, XM_011529971.1:c.841+39G>A, XM_011529972.1:c.844-169G>A, XM_011547541.1:c.724G>A, XM_011547750.1:c.841+39G>A, XM_011547751.1:c.769+39G>A, XM_011548819.1:c.724G>A, XP_011545843.1:p.Glu242Lys, XP_011547121.1:p.Glu242Lys, XR_952745.1:n.2001-169G>A, rs57124011, rs587777916		C > T	SNP
VIP	CYP2D6	rs35742686	NC_000022.10:g.42524244delT, NC_000022.11:g.42128242delT, NG_008376.3:g.6750delA, NM_000106.5:c.775delA, NM_001025161.2:c.622delA, NP_000097.3:p.Arg259Glyfs, NP_001020332.2:p.Arg208Glyfs, NT_187682.1:g.50583delT, NW_004504305.1:g.50569delT, NW_009646208.1:g.13808delT, XM_005278353.1:c.631delA, XM_005278354.1:c.475delA, XM_005278354.3:c.475delA, XM_011529966.1:c.775delA, XM_011529967.1:c.775delA, XM_011529968.1:c.775delA, XM_011529969.1:c.631delA, XM_011529970.1:c.622delA, XM_011529971.1:c.631delA, XM_011529972.1:c.775delA, XM_011547541.1:c.475delA, XM_011547750.1:c.631delA, XM_011547751.1:c.559delA, XM_011547756.1:c.-1793delT, XM_011548819.1:c.475delA, XP_005278410.1:p.Arg211Glyfs, XP_005278411.1:p.Arg159Glyfs, XP_011528268.1:p.Arg259Glyfs, XP_011528269.1:p.Arg259Glyfs, XP_011528270.1:p.Arg259Glyfs, XP_011528271.1:p.Arg211Glyfs, XP_011528272.1:p.Arg208Glyfs, XP_011528273.1:p.Arg211Glyfs, XP_011528274.1:p.Arg259Glyfs, XP_011545843.1:p.Arg159Glyfs, XP_011546052.1:p.Arg211Glyfs, XP_011546053.1:p.Arg187Glyfs, XP_011547121.1:p.Arg159Glyfs, XR_430455.2:n.-1629delT, XR_952745.1:n.1932delA, rs45593132, rs60790764		T > - T > T	indel	R259G
VIP VA	CYP2D6	rs3892097	NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227	codeine	C > T	SNP
VIP	CYP2D6	rs5030655	NC_000022.10:g.42525086delA, NC_000022.11:g.42129084delA, NG_008376.3:g.5908delT, NM_000106.5:c.454delT, NM_001025161.2:c.353-140delT, NP_000097.3:p.Trp152Glyfs, NT_187682.1:g.51425delA, NW_004504305.1:g.51411delA, NW_009646208.1:g.14650delA, XM_005278353.1:c.363-141delT, XM_005278354.1:c.155delT, XM_005278354.3:c.155delT, XM_011529966.1:c.454delT, XM_011529967.1:c.454delT, XM_011529968.1:c.454delT, XM_011529969.1:c.311delT, XM_011529970.1:c.353-140delT, XM_011529971.1:c.311delT, XM_011529972.1:c.454delT, XM_011547541.1:c.155delT, XM_011547750.1:c.311delT, XM_011547751.1:c.238delT, XM_011547756.1:c.-951delA, XM_011548819.1:c.155delT, XP_005278411.1:p.Val52Glyfs, XP_011528268.1:p.Trp152Glyfs, XP_011528269.1:p.Trp152Glyfs, XP_011528270.1:p.Trp152Glyfs, XP_011528271.1:p.Val104Glyfs, XP_011528273.1:p.Val104Glyfs, XP_011528274.1:p.Trp152Glyfs, XP_011545843.1:p.Val52Glyfs, XP_011546052.1:p.Val104Glyfs, XP_011546053.1:p.Trp80Glyfs, XP_011547121.1:p.Val52Glyfs, XR_430455.2:n.-787delA, XR_952745.1:n.1611delT, rs11568727, rs28371709		A > - A > A	indel	W152G
VIP	CYP2D6	rs5030656	NC_000022.10:g.42524176_42524178delCTT, NC_000022.11:g.42128174_42128176delCTT, NG_008376.3:g.6816_6818delAAG, NM_000106.5:c.841_843delAAG, NM_001025161.2:c.688_690delAAG, NP_000097.3:p.Lys281del, NP_001020332.2:p.Lys230del, NT_187682.1:g.50515_50517delCTT, NW_004504305.1:g.50501_50503delCTT, NW_009646208.1:g.13740_13742delCTT, XM_005278353.1:c.697_699delAAG, XM_005278354.1:c.541_543delAAG, XM_005278354.3:c.541_543delAAG, XM_011529966.1:c.841_843delAAG, XM_011529967.1:c.841_843delAAG, XM_011529968.1:c.841_843delAAG, XM_011529969.1:c.697_699delAAG, XM_011529970.1:c.688_690delAAG, XM_011529971.1:c.697_699delAAG, XM_011529972.1:c.841_843delAAG, XM_011547541.1:c.541_543delAAG, XM_011547750.1:c.697_699delAAG, XM_011547751.1:c.625_627delAAG, XM_011547756.1:c.-1861_-1859del, XM_011548819.1:c.541_543delAAG, XP_005278410.1:p.Lys233del, XP_005278411.1:p.Lys181del, XP_011528268.1:p.Lys281del, XP_011528269.1:p.Lys281del, XP_011528270.1:p.Lys281del, XP_011528271.1:p.Lys233del, XP_011528272.1:p.Lys230del, XP_011528273.1:p.Lys233del, XP_011528274.1:p.Lys281del, XP_011545843.1:p.Lys181del, XP_011546052.1:p.Lys233del, XP_011546053.1:p.Lys209del, XP_011547121.1:p.Lys181del, XR_430455.2:n.-1697_-1695del, XR_952745.1:n.1998_2000delAAG, rs587777919		CTT > - CTT > CTT	indel
VIP	CYP2D6	rs59421388	NC_000022.10:g.42523610C>T, NC_000022.11:g.42127608C>T, NG_008376.3:g.7384G>A, NM_000106.5:c.1012G>A, NM_001025161.2:c.859G>A, NP_000097.3:p.Val338Met, NP_001020332.2:p.Val287Met, NT_187682.1:g.49949C>T, NW_004504305.1:g.49935C>T, NW_009646208.1:g.13174C>T, XM_005278353.1:c.868G>A, XM_005278354.1:c.712G>A, XM_005278354.3:c.712G>A, XM_011529966.1:c.1012G>A, XM_011529967.1:c.1012G>A, XM_011529968.1:c.1012G>A, XM_011529969.1:c.868G>A, XM_011529970.1:c.859G>A, XM_011529971.1:c.868G>A, XM_011529972.1:c.870G>A, XM_011547541.1:c.*118G>A, XM_011547750.1:c.868G>A, XM_011547751.1:c.796G>A, XM_011548819.1:c.*118G>A, XP_005278410.1:p.Val290Met, XP_005278411.1:p.Val238Met, XP_011528268.1:p.Val338Met, XP_011528269.1:p.Val338Met, XP_011528270.1:p.Val338Met, XP_011528271.1:p.Val290Met, XP_011528272.1:p.Val287Met, XP_011528273.1:p.Val290Met, XP_011528274.1:p.Thr290=, XP_011546052.1:p.Val290Met, XP_011546053.1:p.Val266Met, XR_952745.1:n.2027G>A		C > T	SNP	V338M
VIP	CYP2D6	rs61736512	NC_000022.10:g.42525134C>T, NC_000022.11:g.42129132C>T, NG_008376.3:g.5860G>A, NM_000106.5:c.406G>A, NM_001025161.2:c.353-188G>A, NP_000097.3:p.Val136Met, NT_187682.1:g.51473C>T, NW_004504305.1:g.51459C>T, NW_009646208.1:g.14698C>T, XM_005278353.1:c.363-189G>A, XM_005278354.1:c.107G>A, XM_005278354.3:c.107G>A, XM_011529966.1:c.406G>A, XM_011529967.1:c.406G>A, XM_011529968.1:c.406G>A, XM_011529969.1:c.263G>A, XM_011529970.1:c.353-188G>A, XM_011529971.1:c.263G>A, XM_011529972.1:c.406G>A, XM_011547541.1:c.107G>A, XM_011547750.1:c.263G>A, XM_011547751.1:c.190G>A, XM_011547756.1:c.-903C>T, XM_011548819.1:c.107G>A, XP_005278411.1:p.Arg36His, XP_011528268.1:p.Val136Met, XP_011528269.1:p.Val136Met, XP_011528270.1:p.Val136Met, XP_011528271.1:p.Arg88His, XP_011528273.1:p.Arg88His, XP_011528274.1:p.Val136Met, XP_011545843.1:p.Arg36His, XP_011546052.1:p.Arg88His, XP_011546053.1:p.Val64Ile, XP_011547121.1:p.Arg36His, XR_430455.2:n.-739C>T, XR_952745.1:n.1563G>A		C > T	SNP	V136M
VA		rs61737947		codeine		unknown
CA VA	UGT2B7	rs7439366	NC_000004.11:g.69964338T>C, NC_000004.12:g.69098620T>C, NM_001074.2:c.802T>C, NP_001065.2:p.Tyr268His, XM_005265702.1:c.55T>C, XM_005265702.2:c.55T>C, XM_011532229.1:c.802T>C, XM_011532230.1:c.802T>C, XM_011532231.1:c.55T>C, XP_005265759.1:p.Tyr19His, XP_011530531.1:p.Tyr268His, XP_011530532.1:p.Tyr268His, XP_011530533.1:p.Tyr19His, rs34924067, rs57980137	codeine	T > C	SNP	Y268H
VIP	CYP3A5	rs776746	NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770		C > T	SNP

[ see larger image ] [ see 3D structure ]

provided by PubChem

Overview

PharmGKB Accession Id

PA449088

Type(s):

Prodrug

Other Vocabularies

• ATC: Natural opium alkaloids (N02AA)
• ATC: Opium alkaloids and derivatives (R05DA)
• UMLS: Codeine (C0009214)
• RxNorm: Codeine (2670)
• NDFRT: CODEINE (N0000145894)

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Absorption, Distribution, Metabolism, Elimination & Toxicity

Chemical Properties

[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O

InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

1. Codeine and Morphine Pathway, Pharmacokinetics
   Representation of the candidate genes involved in metabolism of codeine and morphine.

Publications related to codeine: 101

	Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6. Pharmacogenomics and personalized medicine. 2017. Takahashi Paul Y, et al.
	The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert opinion on drug metabolism & toxicology. 2016. Tverdohleb Tatiana, et al.
	Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease. Pediatrics. 2016. Gammal Roseann S, et al.
	Codeine in paediatrics: pharmacology, prescribing and controversies. Archives of disease in childhood. Education and practice edition. 2016. Andrzejowski Paul, et al.
	Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016. Hocum Brian Thomas, et al.
	The outlier in all of Us: Why implementing pharmacogenomics could matter for everyone. Clinical pharmacology and therapeutics. 2016. O'Donnell Peter H, et al.
	Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Tracy Timothy S, et al.
	Pharmacogenomically actionable medications in a safety net health care system. SAGE open medicine. 2016. Carpenter Janet S, et al.
	Integrated Patient and Tumor Genetic Testing for Individualized Cancer Therapy. Clinical pharmacology and therapeutics. 2015. Hertz Daniel L, et al.
CA VA	The pharmacogenetics of codeine pain relief in the postpartum period. The pharmacogenomics journal. 2015. Baber M, et al.
	Metabolism and Disposition of Prescription Opioids: A Review. Forensic science review. 2015. DePriest A Z, et al.
	Pharmacogenetics of opioid response. Clinical pharmacology and therapeutics. 2015. Somogyi A A, et al.
	CYP2D6 Phenotype-Specific Codeine Population Pharmacokinetics. Journal of pain & palliative care pharmacotherapy. 2015. Linares Oscar A, et al.
	Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2015. McMillan Douglas M, et al.
	Oxycodone overdose in the pediatric population: case files of the University of Massachusetts Medical Toxicology Fellowship. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2014. Boyle Katherine L, et al.
	CYP2D6 and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics. 2014. Gaedigk Andrea, et al.
	Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update. Clinical pharmacology and therapeutics. 2014. Crews Kristine R, et al.
	Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Current drug metabolism. 2014. Caudle Kelly E, et al.
CA VA	The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects. European journal of clinical pharmacology. 2013. Wu Xiujun, et al.
	New evidence about an old drug--risk with codeine after adenotonsillectomy. The New England journal of medicine. 2013. Racoosin Judith A, et al.
	Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al.
	First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. Biochemical pharmacology. 2013. Zhou Kaidi, et al.
	Codeine-associated pediatric deaths despite using recommended dosing guidelines: three case reports. Journal of opioid management. 2013. Friedrichsdorf Stefan J, et al.
	Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. Journal of population therapeutics and clinical pharmacology = Journal de la thérapeutique des populations et de la pharamcologie clinique. 2013. Madadi Parvaz, et al.
	Cytochrome P450-mediated drug metabolism in the brain. Journal of psychiatry & neuroscience : JPN. 2012. Miksys Sharon, et al.
	Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study. Paediatric drugs. 2012. Khetani Justin D, et al.
	A Clinician-Driven Automated System for Integration of Pharmacogenetic Interpretations Into an Electronic Medical Record. Clinical pharmacology and therapeutics. 2012. Hicks J K, et al.
VIP	PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics and genomics. 2012. Lamba Jatinder, et al.
CA VA	More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012. Kelly Lauren E, et al.
CA VA	Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clinical pharmacology and therapeutics. 2012. Sistonen J, et al.
	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype. Clinical pharmacology and therapeutics. 2011. Crews K R, et al.
CA VA	CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Therapeutic drug monitoring. 2011. VanderVaart Sondra, et al.
	Pharmacogenetic testing: time for clinical practice guidelines. Clinical pharmacology and therapeutics. 2011. Amstutz U, et al.
	Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs. Regulatory toxicology and pharmacology : RTP. 2011. Volpe Donna A, et al.
	Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al.
	Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al.
	Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics. 2011. Meyer Markus R, et al.
	The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study. Journal of population therapeutics and clinical pharmacology = Journal de la thérapeutique des populations et de la pharamcologie clinique. 2011. Madadi Parvaz, et al.
	Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al.
	Maternal-fetal and neonatal pharmacogenomics: a review of current literature. Journal of perinatology : official journal of the California Perinatal Association. 2010. Blumenfeld Y J, et al.
	Personalized therapy in pain management: where do we stand?. Pharmacogenomics. 2010. Stamer Ulrike M, et al.
	Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. The lancet oncology. 2010. Relling Mary V, et al.
	Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. British journal of clinical pharmacology. 2010. Mannheimer Buster, et al.
CA VA	Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease. European journal of clinical pharmacology. 2010. Molanaei Hadi, et al.
	Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study. Clinical pharmacology and therapeutics. 2009. Willmann S, et al.
	Guidelines for maternal codeine use during breastfeeding. Canadian family physician Médecin de famille canadien. 2009. Madadi Parvaz, et al.
CA VA	O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. European journal of clinical pharmacology. 2009. Vevelstad M, et al.
CA VA	Codeine, ultrarapid-metabolism genotype, and postoperative death. The New England journal of medicine. 2009. Ciszkowski Catherine, et al.
CA VA	The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease. European journal of clinical pharmacology. 2009. Shord Stacy S, et al.
CA VA	Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?. Pain. 2009. Lötsch Jörn, et al.
	Codeine and morphine pathway. Pharmacogenetics and genomics. 2009. Thorn Caroline F, et al.
VIP	Cytochrome P450 2D6. Pharmacogenetics and genomics. 2009. Owen Ryan P, et al.
	Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenetics and genomics. 2009. Lötsch Jörn, et al.
CA VA	Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clinical pharmacology and therapeutics. 2009. Madadi P, et al.
CA VA	Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes. Drug metabolism and disposition: the biological fate of chemicals. 2009. Zhang Wei-Yan, et al.
	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al.
CA VA	Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anesthesia and analgesia. 2008. Stamer Ulrike M, et al.
	Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008. Madadi Parvaz, et al.
	Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics. 2008. Rollason Victoria, et al.
CA VA	Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals. 2007. Shen Hongwu, et al.
CA VA	Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. The pharmacogenomics journal. 2007. Kirchheiner J, et al.
VA	Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. Paediatric anaesthesia. 2007. Voronov Polina, et al.
CA VA	The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. The Journal of pediatrics. 2007. Brousseau David C, et al.
CA VA	Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Progress in neuro-psychopharmacology & biological psychiatry. 2006. Susce Margaret T, et al.
CA VA	Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006. Koren Gideon, et al.
	Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clinical pharmacology and therapeutics. 2006. Lötsch Jörn, et al.
CA VA	Codeine intoxication associated with ultrarapid CYP2D6 metabolism. The New England journal of medicine. 2004. Gasche Yvan, et al.
	Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug metabolism and disposition: the biological fate of chemicals. 2003. Court Michael H, et al.
CA VA	Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. Journal of clinical psychopharmacology. 2003. de Leon Jose, et al.
	Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. British journal of anaesthesia. 2002. Williams D G, et al.
CA VA	Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. The Journal of pharmacology and experimental therapeutics. 2002. Yu Aiming, et al.
	Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. Journal of clinical psychopharmacology. 2002. Fernandes Leona C, et al.
VA	The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clinical pharmacology and therapeutics. 2002. Wennerholm Agneta, et al.
	Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al.
	No pain relief from codeine...? An introduction to pharmacogenomics. Acta anaesthesiologica Scandinavica. 2001. Fagerlund T H, et al.
	Codeine analgesia is due to codeine-6-glucuronide, not morphine. International journal of clinical practice. 2000. Vree T B, et al.
	Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. European journal of clinical pharmacology. 1998. Poulsen L, et al.
	Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain. 1998. Eckhardt K, et al.
CA VA	A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Molecular pharmacology. 1997. Oscarson M, et al.
	Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity. Therapeutic drug monitoring. 1997. Hedenmalm K, et al.
	Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 1997. Tyndale R F, et al.
CA VA	Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Therapeutic drug monitoring. 1997. Dalén P, et al.
CA VA	Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clinical pharmacology and therapeutics. 1997. Mikus G, et al.
	Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. The Journal of pharmacology and experimental therapeutics. 1997. Kaplan H L, et al.
	Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects. The Journal of pharmacology and experimental therapeutics. 1997. Caraco Y, et al.
	Human UGT2B7 catalyzes morphine glucuronidation. Drug metabolism and disposition: the biological fate of chemicals. 1997. Coffman B L, et al.
	The effect of codeine on gastrointestinal transit in extensive and poor metabolisers of debrisoquine. European journal of clinical pharmacology. 1997. Hasselström J, et al.
	Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. The Journal of pharmacology and experimental therapeutics. 1996. Caraco Y, et al.
CA VA	Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clinical pharmacology and therapeutics. 1996. Tseng C Y, et al.
	Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. European journal of clinical pharmacology. 1996. Poulsen L, et al.
	Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. British journal of clinical pharmacology. 1995. Persson K, et al.
	Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life sciences. 1995. Mignat C, et al.
	The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model. The Journal of pharmacology and experimental therapeutics. 1994. Cleary J, et al.
	Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. British journal of clinical pharmacology. 1991. Chen Z R, et al.
	Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clinical pharmacology and therapeutics. 1990. Sindrup S H, et al.
VIP	Impact of environmental and genetic factors on codeine analgesia. European journal of clinical pharmacology. 1991. Desmeules J, et al.
	Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1. Clinical pharmacology and therapeutics. 1990. Mortimer O, et al.
	Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. British journal of clinical pharmacology. 1989. Yue Q Y, et al.
	Polymorphic O-demethylation of codeine. Lancet. 1988. Chen Z R, et al.
	Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochemical and biophysical research communications. 1988. Dayer P, et al.
	http://www.sciencenews.org/sn_arc97/9_13_97/fob2.htm. [URL:http://www.sciencenews.org/sn_arc97/9_13_97/fob2.htm]

LinkOuts